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Abstract 
Imatinib therapy has improved outcomes in advanced GISTs. Current guidelines suggest monitoring with CT 
scanning every 12 weeks. There are no validated biomarkers to assist disease evaluation. We identified 50 
patients treated with imatinib for GIST in a single tertiary centre. We assessed the prognostic value of d-
dimers by Cox regression, and the utility as a biomarker for radiological progression (rPD) using receiver-
operator curve (ROC) analysis. In asymptomatic patients with d-dimer levels <1000 and falling levels, the 
negative predictive value for rPD was 92%. D-dimers may reduce the burden of CT scanning in a proportion 
of patients in this setting. 
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Background 
The use of imatinib, a molecularly targeted agent against the tyrosine kinase receptor, has led to improved 
tumour control and a survival advantage in patients with locally advanced and metastatic GISTs1–3.  Benefits 
have also been seen in second line treatment with sunitinib, following progression with, or intolerance of, 
imatinib.  With the availability of second line therapies, disease monitoring whilst on imatinib is important to 
identify cancer progression in a timely manner.  CT scanning is the imaging modality recommended by 
established guidelines for routine monitoring.  Specific guidelines suggest that CT scans to assess response 
should be performed up to 3 monthly, for an indefinite time period4–7.  Such frequent scanning aims to 
identify progression early, but as patients may remain progression-free for a number of years, it comes with a 
burden of cost, radiation exposure and consequences for the patient experience.  In contrast to other 
cancers, there are currently no non-radiological biomarkers to aid in the response assessment of GIST. 
D-dimers are commonly used in the diagnostic assessment algorithm for the exclusion of venous thrombosis 
due to their high negative predictive value (NPV) for this condition8.  They are also raised in other conditions 
and therefore have a poor positive predictive value (PPV).  As a result D-dimers are useful for ruling-out, 
rather than ruling-in, thrombosis.  D-dimers are frequently raised in the presence of active cancer and are 
associated with poor survival outcomes9.  For this reason it seems possible that they can help to rule out 
active or progressing cancer. 
D-dimers have been measured approximately 3-monthly in patients with advanced GIST in our centre over 
the last 10 years.  We investigated whether D-dimers can predict disease progression in patient with GIST 
treated with palliative imatinib therapy.  The objective was to determine if D-dimers can offer sufficient 
negative predictive value for radiological progression to reduce the frequency of CT scanning. 
Patients & Methods 
Patients were eligible for inclusion in the study if they had been treated with imatinib as palliative treatment 
for histologically confirmed incurable GIST between 1st January 2000 and 1st January 2010.  The study was 
limited to St. James’s University Hospital in Leeds, UK which is a single large tertiary referral centre.  
Patients were identified retrospectively using a systematic search of an electronic patient records database 
(Patient Pathway Manager - PPM10).  Patients were excluded if their care was transferred to another centre 
or if they were treated elsewhere under advice from St. James’s University Hospital.  Baseline clinical 
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characteristics were recorded and were pre-defined as age at presentation, sex, performance status, site of 
primary tumour, presence of metastases at presentation, neutrophil count and baseline D-dimer level.  
Routine follow-up consisted of clinic attendance with clinical assessment at 3-monthly intervals with a D-
dimer blood test before each visit and a CT scan at 3 monthly intervals (alternate clinic visits).  The D-dimers 
were analysed using the HemosIL D-dimer Kit by Beckman Coulter. 
Endpoint definitions 
Response assessment was measured by CT scan reported to standard criteria (the adopted criterion in the 
department was changed from RECIST to Choi in 2004).  Clinical benefit was defined as complete response, 
partial response or stable disease.  Day zero was taken as the date of the commencement of imatinib.  
Survival endpoints were progression free survival (PFS) and overall survival (OS).  PFS was defined as time 
to first radiological evidence of progression or death from any cause, with patients censored at last follow-up.  
OS was defined as time to death from any cause, with patients censored at last follow-up. 
The D-dimer measurement associated with each scan was that taken closest to each CT scan date.  Any D-
dimer measurement that was taken more than 30 days either side of the CT scan was excluded.  
Assessment of the ability of D-dimers to exclude radiological progression took two separate approaches.  
The first (“D-dimer level”) took the reported value at the time of the scan.  The second approach (“D-dimer 
trend”) took the difference in the level between two sequential scans, irrespective of the time interval 
between measurements. 
Statistical Analysis 
The Kaplan-Meier method was used for survival analysis.  A log-rank test was used to test for significant 
prognostic ability of baseline D-dimer levels.  Adjustment for baseline clinical characteristics previously 
identified as prognostic in advanced GIST was undertaken using the Cox proportional hazards model11–13.  
Genetic mutation analysis was not conducted in patients diagnosed early in the series therefore this was not 
considered.  Highly correlated variables were excluded if they demonstrated an absolute correlation 
coefficient > 0.4 using a Spearman rank correlation (no variables required exclusion).  D-dimer level was also 
included in a Cox-proportional hazards model as a time-dependent co-variate14.  The D-dimer level at the 
time of each CT scan was compared to the response assessment (progressive disease vs clinical benefit) 
with medians compared using the Wilcoxon rank sum test.  The mean change (trend) was compared using a 
Welch’s t-test.  A two-sided p-value of less than 0.05, in all tests, was considered statistically significant.  
Receiver operating characteristic (ROC) analysis was conducted using established methods15.  The 
Page 4 of 18
URL: http://mc.manuscriptcentral.com/lcnv E-mail: glyman@fhcrc.org
Cancer Investigation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Page 5 of 12 
predictive ability of both the absolute D-dimer level and the trend (change over time) was assessed.  R 
version 2.11.1 was used for the statistical analysis16. 
Results 
A total of 50 patients were included in the study.  Patient characteristics are summarized in Table 1. There 
were no patients diagnosed with venous thromboembolism during the study period. 
The median follow-up at the time of analysis (January 2012) was 3.7 years overall or 4.7 years in patients 
who remain alive and progression-free.   41 patients (82%) experienced events meeting the definition of 
PFS.  The median PFS was 2.2 years.  29 patients (58%) had died and the median OS was 4.9 years. 
D-dimers as a prognostic indicator 
A baseline D-dimer measurement of >1000 ng/ml was prognostic for PFS (p = 0.00002, unadjusted hazard 
ratio 5.55) and OS (p = 0.000007, unadjusted hazard ratio 7.9) (Figure 1).  This remained significant when 
adjusted for all other baseline factors in bivariate and multivariable analysis.  D-dimers were more strongly 
prognostic for PFS and OS when analysed as a continuous time-dependent covariate. 
D-dimers as a predictor of disease activity 
In total, across all patients there were 460 observation points which included a CT scan, D-dimer 
measurement and clinical assessment.  The median D-dimer level when there was no radiological evidence 
of progression was 411 ng/ml (IQR 233 – 691) compared to a median level in patients with radiological 
evidence of progression of 609 ng/ml (IQR 342 – 1770) (p = <0.0001 ).  The median level when there was 
radiological or symptomatic evidence for progression was 1238 ng/ml (IQR 591 – 2528) (Figure 2a). 
Looking at the change in D-dimer level compared with that measured at the time of the previous scan (trend), 
the median change prior to a scan with no evidence of radiological progression was 0 ng/ml (IQR -65 – 67).  
Patients with radiological evidence of progression had a median change of 80 ng/ml (IQR 0 – 339) (p 
<0.0001).  The median level of change when there was both radiological and symptomatic evidence of 
progression was 189 ng/ml (IQR 0 – 892) (Figure 2b).  
ROC curves are presented in Figure 3 for both D-dimer levels, and change in D-dimer levels, demonstrating 
the sensitivity and specificity as a biomarker for radiological progression.  The area under the ROC curve 
(AUC) was 0.64 and 0.65 respectively. 
D-dimers as a surrogate marker to exclude radiological progression 
The odds for radiological progression, given different D-dimer levels, change in D-dimer levels prior to a 
scan, and the presence or absence of clinical symptoms are presented in Figure 4.  Falling D-dimers are 
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associated with odds for radiological progression of 0.28 (95% CI 0.15 – 0.48, p=<0.001), are seen in 39% of 
observations and have a negative predictive value (NPV) for excluding radiological progression of 0.91.  The 
ability of D-dimers to exclude radiological progression is improved by considering patients with falling D-
dimers and a level less than or equal to 900 ng/ml.  In this case the odds for radiological progression is 0.26 
(95% CI 0.13 – 0.47, p=<0.001) with a NPV of 0.92 in 35% of observations.  This is improved further by also 
considering the absence of clinical symptoms of progression which, when combined with falling D-dimers 
below the level of 900 ng/ml gives an odds for progression of 0.23 (95% CI 0.11 – 0.43, p<0.001) and a NPV 
of 0.93, seen in 33% of observations. 
Discussion 
Imatinib has greatly improved outcomes in advanced GIST, and these have been further improved with 
second line therapy using sunitinib.  With further therapeutic options and the potential for patients to be 
monitored on treatment for many months or years, optimal monitoring strategies are vital.  Current strategies 
are formalized by a number of clinical guidelines including those by the European Society for Medical 
Oncology, US National Comprehensive Cancer Network, and the UK National Institute for Health and Clinical 
Excellence4–6.  For patients on active palliative systemic therapy, monitoring is recommended every 3 months 
using CT scanning.  There is little empirical evidence to support this recommendation and such frequent 
scanning, often over many months or years, places an emotional burden on patients, potentially unnecessary 
radiation exposure and a financial burden on health service providers. 
The results presented here suggest that D-dimer monitoring offers useful information about progression 
status.  We suggest that a combination of three criteria can be considered reassuring of non-progression: i) 
no clinical evidence of progression, ii) a fall in the D-dimer level since the previous measurement and, iii) a 
D-dimer level less than 900 ng/ml.  The NPV for progression in patients meeting all these criteria is 0.93.  
This suggests that CT scanning can safely be foregone in patients meeting these criteria.  The benefits of 
adopting D-dimer-directed CT scanning would be to reduce the burden of scans by approximately a third.  
The negative consequences would be to introduce a delay to diagnosis in around 7% of true progression 
events.  This delay would be incurred until such a time as either the D-dimer level stabilized or rose, or the 
patient developed symptoms of progression. 
Our conclusions make the assumption that our gold-standard test, the CT scan, is a perfect indicator of 
progression status.  However, radiological evaluation is not straight forward for GIST and the interpretation of 
CT findings can vary between tumours depending upon their size, stage and aggressiveness.  Treatment 
with imatinib can typically take up to 1 year to fulfil RECIST response criteria and it has been demonstrated 
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that response assessed by RECIST does not correlate well with time to progression17,18.  The Choi criteria 
may improve on RECIST for assessment of response by also taking into account tumour density but,  
regardless of criteria used, CT scans may not always detect progression.  Tumours may enlarge in the 
context of a response, and progression may only be evident by the development of nodules within an 
existing tumour.  FDG-PET may offer improved test performance for the detection of progression, but its use 
for serial monitoring is limited by accessibility and cost18–20.  We found no data reporting the sensitivity and 
specificity of imaging modalities for the detection of progression.  For these reasons, our reported NPV for D-
dimers needs to be interpreted in relation to CT progression detection rather than more meaningful patient 
outcomes. 
There are currently no validated biomarkers to aid in response assessment or detection of progression in 
GIST.  There are a number of other precedents supporting the use of tumour markers to provide information 
about progression status.  This is perhaps most notable in the case of germ cell tumours, which secrete 
HCG or -fetoprotein, where tumour markers correlate very strongly with progression and may frequently 
pre-date radiological detectability; monitoring is a core component of follow-up guidelines21.  The marker CA-
125 is highly correlated with progression status in ovarian cancer22 and CEA is used to monitor the treatment 
of colorectal cancer. 
The activation of the coagulation system is associated with the immune response that accompanies active 
malignancy.  D-dimer is a fibrin degradation product present in the blood when following the activation of the 
coagulation cascade.  There is therefore a mechanistic theory that supports D-dimers as a biomarker for 
cancer activity.  In a number of published studies, D-dimers have been shown to be related to cancer, with 
high levels associated with the presence of malignancy, higher levels seen in metastatic compared with 
earlier stage disease and raised in those with active cancer compared to patients in remission23–25.  D-dimer 
levels and changes have demonstrated a relationship with progression status in other studies in lung cancer 
and breast cancer26,27.  As well as being predictive for progression, our data suggests that a high baseline D-
dimer is also a prognostic marker for overall survival and progression-free survival.  High D-dimer levels at 
baseline are a poor prognostic sign in several cancers and predictive of lymph node metastases in breast, 
colorectal and oesophageal cancers25,27–36.  Interestingly, in one study, D-dimers were more prognostic for 
survival than CEA in colorectal cancer patients37.  We therefore suggest that D-dimers could usefully be 
incorporated into future baseline staging information and considered in the formulation of future prognostic 
algorithms. 
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The methods for testing and validating tumour markers for use as a monitoring test are under-developed and 
standards have not yet been formalised38.  It seems reasonable to believe that the rate of change over time 
rather than the absolute level is likely to more accurately reflect cancer activity.  It is therefore disappointing 
that many tumour markers are interpreted on the basis of an absolute value in relation to normal ranges22.  
This may in part explain the failure of tumour marker monitoring to impact on clinical outcomes in 
randomised controlled trials39.  The methods used in our analysis of D-dimers for GIST demonstrate how 
decision criteria can maximise the performance of the monitoring test, by combining the absolute level, the 
rate of change and clinical assessment. 
The limitations of this study are that it is a single centre study relying on retrospective data collection.  The 
criteria for interpreting CT tumour status also changed during the 10 years over which our data were 
collected and this may have led to some inconsistency in reporting and identification of progression dates.  
Our data also reflects real-world practice rather than being driven by a research protocol.  This has some 
advantages in generalisability to clinical practice, but the findings may have been compromised by factors 
such as the variability in D-dimer and CT monitoring frequency and non-standard interpretation of findings.  
Clinical management also evolved during our study as new therapeutic options were introduced such as c-kit 
directed therapy and second line treatments. 
The next steps in the development of D-dimers as a monitoring test would be to repeat the analysis in a 
separate independent dataset. Following this it may be appropriate to study the effect of D-dimer monitoring 
on clinical outcomes in the setting of a randomised controlled trial. We would, however, suggest that D-
dimers may be usefully adopted to reduce the burden of frequent CT scanning in patients who have 
experienced a symptomatic and radiological benefit from imatinib and who remain clinically stable. 
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